Long-term remission with eculizumab in atypical haemolytic uraemic syndrome

被引：2

作者：

Carter, Simon ^{[1
]}

Hewitt, Ian ^{[4
]}

Kausman, Joshua ^{[1
,2
,3
]}

机构：

[1] Royal Childrens Hosp, Melbourne, Vic, Australia

[2] Murdoch Childrens Res Inst, Murdoch, WA, Australia

[3] Univ Melbourne, Melbourne, Vic, Australia

[4] Princess Margaret Hosp, Perth, WA, Australia

来源：

NEPHROLOGY | 2017年 / 22卷

关键词：

atypical haemolytic uraemic syndrome; eculizumab; long term outcome; paediatric; safety profile;

D O I：

10.1111/nep.12932

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The understanding of the role of complement dysregulation in atypical haemolytic uraemic syndrome (aHUS) has led to major changes in therapeutic approaches and outcomes. Eculizumab is a humanized anti-C5 monoclonal antibody that inhibits the terminal complement pathway and has revolutionized the treatment and prognosis of aHUS. However, published reports to date have had relatively short-term follow-up. We report two paediatric cases of aHUS successfully treated with eculizumab longer than 6years with no serious adverse events and preservation of renal function.

引用

下载

页码：7 / 10

页数：4

共 50 条

[1] LONG-TERM IMPROVEMENTS IN OUTCOMES WITH ECULIZUMAB IN PATIENTS WITH ATYPICAL HAEMOLYTIC URAEMIC SYNDROME AND PROGRESSING TMA
Sheerin, Neil
Legendre, Christophe
Greenbaum, Larry
Furman, Richard
Cohen, David
Gaber, A. Osama
Bedrosian, Camille
Loirat, Chantal
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 310 - 310
[2] Eculizumab in secondary atypical haemolytic uraemic syndrome
Cavero, Teresa
Rabasco, Cristina
Lopez, Antia
Roman, Elena
Avila, Ana
Sevillano, Angel
Huerta, Ana
Rojas-Rivera, Jorge
Fuentes, Carolina
Blasco, Miquel
Jarque, Ana
Garcia, Alba
Mendizabal, Santiago
Gavela, Eva
Macia, Manuel
Quintana, Luis F.
Maria Romera, Ana
Borrego, Josefa
Arjona, Emi
Espinosa, Mario
Portoles, Jose
Gracia-Iguacel, Carolina
Gonzalez-Parra, Emilio
Aljama, Pedro
Morales, Enrique
Cao, Mercedes
Rodriguez de Cordoba, Santiago
Praga, Manuel
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (03) : 466 - 474
[3] Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study
Menne, Jan
Delmas, Yahsou
Fakhouri, Fadi
Kincaid, John F.
Licht, Christoph
Minetti, Enrico E.
Mix, Chris
Provot, Francois
Rondeau, Eric
Sheerin, Neil S.
Wang, Jimmy
Weekers, Laurent E.
Greenbaum, Larry A.
CLINICAL KIDNEY JOURNAL, 2019, 12 (02) : 196 - 205
[4] Renal Recovery After Long-term Dialysis In A Paediatric Patient With Atypical Haemolytic Uraemic Syndrome Treated With Eculizumab
Emirova, Khadizha
Tolstova, Evgeniya
Muzurov, Alexandr
Makulova, Anastasya
Zverev, Dmitry
Generalova, Galina
Pankratenko, Taniana
Orlova, Olga
PEDIATRIC NEPHROLOGY, 2014, 29 (09) : 1757 - 1757
[5] Eculizumab for atypical haemolytic uraemic syndrome: what next?
Fakhouri, Fadi
Fremeaux-Bacchi, Veronique
NATURE REVIEWS NEPHROLOGY, 2013, 9 (09) : 495 - 496
[6] Early treatment with eculizumab in atypical haemolytic uraemic syndrome
Garjau, Maria
Azancot, Maria
Ramos, Rosa
Sanchez-Corral, Pilar
Angeles Montero, Maria
Seron, Daniel
CLINICAL KIDNEY JOURNAL, 2012, 5 (01) : 31 - 33
[7] Eculizumab for atypical haemolytic uraemic syndrome: what next?
Fadi Fakhouri
Véronique Frémeaux-Bacchi
Nature Reviews Nephrology, 2013, 9 : 495 - 496
[8] PROGRESSING THROMBOTIC MICROANGIOPATHY IN ATYPICAL HAEMOLYTIC URAEMIC SYNDROME PATIENTS: LONG TERM IMPROVEMENTS IN OUTCOMES WITH ECULIZUMAB
Douglas, K.
Sheerin, N.
Legendre, C.
Greenbaum, L.
Furman, R.
Cohen, D.
Bedrosian, C.
Loirat, C.
HAEMATOLOGICA, 2013, 98 : 91 - 92
[9] Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
Gillian M. Keating
Drugs, 2013, 73 : 2053 - 2066
[10] A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Rathbone, John
Kaltenthaler, Eva
Richards, Anna
Tappenden, Paul
Bessey, Alice
Cantrell, Anna
BMJ OPEN, 2013, 3 (11):

← 1 2 3 4 5 →